Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 3Other hematologic neoplasm 2Gastrointestinal 2CNS 2Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 3

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Palonosetron × Tumor-Agnostic × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT03097588 2021-07-12

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

OHSU Knight Cancer Institute

Phase 2 Completed
43 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Ohio State University Comprehensive Cancer Center

Phase NA Completed
40 enrolled 12 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡